Penumbra (NYSE:PEN) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Penumbra (NYSE:PEN) announced its earnings results on Tuesday. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.88 by $0.09, Zacks reports. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.73%. Penumbra updated its FY 2025 guidance to EPS.

Penumbra Price Performance

NYSE:PEN opened at $303.55 on Thursday. The company has a market cap of $11.65 billion, a P/E ratio of 892.79, a P/E/G ratio of 1.99 and a beta of 0.53. The firm’s fifty day moving average price is $256.15 and its two-hundred day moving average price is $225.97. Penumbra has a one year low of $148.00 and a one year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PEN shares. Royal Bank of Canada lifted their price target on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Company increased their target price on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday. Oppenheimer began coverage on shares of Penumbra in a research note on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price objective for the company. Canaccord Genuity Group lifted their target price on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, BTIG Research raised their price target on Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.64.

Insider Transactions at Penumbra

In other Penumbra news, CAO Lambert Shiu sold 1,798 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $242.56, for a total value of $436,122.88. Following the transaction, the chief accounting officer now directly owns 20,682 shares of the company’s stock, valued at $5,016,625.92. This represents a 8.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now directly owns 8,530 shares of the company’s stock, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,219 shares of company stock worth $4,426,439. 5.00% of the stock is owned by insiders.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.